Orales Glibenclamid bei vorzeitiger Hyperglykämie (GALOP) (GALOP)
The purpose of this study is to confirm hypothesis that Glibenclamide can be administered orally and is an alternative to insulin therapy in treating transient hyperglycemia of premature newborns.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Transient hyperglycemia of premature newborns results from an overall decrease in insulin sensitivity, which is responsible at the beta cell level for abnormalities of intragranular cleavage of proinsulin into insulin, leading to reduced active insulin secretion. Intravenous administration of exogenous insulin can be used to combat insulin resistance and lower blood glucose, but it is difficult to manage in premature newborns and is associated with a substantial risk of hypoglycemia. Glibenclamide, which stimulates endogenous insulin secretion and can be administered orally, might be an alternative to insulin therapy in treating transient hyperglycemia of premature newborns.
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
-
Paris, Frankreich, 75015
- Hopital Necker - Enfants malades
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Newborn less than 34 week of amenorrhea corrected age
- Birth weight < 1500 g
- Birth term < 32 week of amenorrhea
- Hyperglycemia ≥ 10 mmol/l in 2 measurements, 3 hours apart after potential reduction of glucose intakes following each department's protocol
- Secure venous access point (umbilical venous catheter or epicutaneo-cava catheter)
- Enteral feeding considered before inclusion or already established
- Consent obtained from persons holding parental authority
- Beneficiary of social security
Exclusion Criteria
- Contraindication to enteral feeding (at the discretion of the clinician responsible for the child)
- Contraindication to glibenclamide according to current SPC
- Foetal growth restriction (FGR) birth weight < 3rd percentile (AUDIPOG definition)
- Severe birth defect, including cardiac malformation associated with a risk of myocardial ischemia
- Severe sepsis requiring mechanical ventilation or haemodynamic support
- Severe renal dysfunction (serum creatinine > 120 µmol/l)
- Severe hepatocellular failure (V factor less than the standard laboratory range for the age) and/or severe cholestasis (> 50 µmol/L)
- Hyperglycemia associated with an error in administering glucose infusion
- Profound hypophosphoremia (< 1 mmol/l)
- Hypersensitivity to glibenclamide or other sulphonylureas or sulphonamides, or one of the excipients
- Patient with continuous insulin IV administration
- Patient treated with miconazole
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Glibenclamide oral
Amglidia®: glibenclamide oral suspension 6 mg/ml administered by gastric tube after dilution to 1/6th in human milk |
Amglidia®: glibenclamide oral suspension 6 mg/ml administered by gastric tube after dilution to 1/6th in human milk
PK parameters of glibenclamide will be determined using nonlinear analysis: area under the plasma concentration time curve (AUC), absorption constant, apparent clearance and volume of distribution. blood sampling at before first administration and after 24 hours for measurement of C-peptide proinsulin ratio if it is impossible to collect both volumes, the C-peptide collection will be prioritized If there are not performed as part of standard care, biological monitoring of ALT, AST, complete blood count, hemostasis, urea, creatinine, blood ionogram, total bilirubin and conjugated bilirubin will be done before first administration at the following time frame : 48 hours after the first administration than each days during treatment period, and 48 hours after the end of treatment. Transaminases and hemostasis will be done only in case of clinical indication before the first administration. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Blood glucose control
Zeitfenster: At 72 hours after the first administration
|
The primary evaluation criteria is 72 hours blood glucose control on glibenclamide treatment (success of the treatment). This is defined as the non-use of insulin and absence of severe hypoglycemia (< 1.5 mmol/l) or persistent moderate hypoglycemia (< 2.6 mmol/l in 2 successive measurements (dextro) at an interval of more than 3 hours) |
At 72 hours after the first administration
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Overall success of the treatment
Zeitfenster: At 36 week of amenorrhea corrected age
|
Overall success of the treatment defined by continuation to the end of treatment without recourse to insulin. |
At 36 week of amenorrhea corrected age
|
|
Blood glucose profile on glibenclamide
Zeitfenster: At the end of treatment assessed up to 15 days
|
Time between the start of glibenclamide treatment and the 1st blood glucose < 10 mmol/l |
At the end of treatment assessed up to 15 days
|
|
Blood glucose profile on glibenclamide
Zeitfenster: At the end of treatment assessed up to 15 days
|
Time between the start of glibenclamide treatment and the 1st blood glucose < 8 mmol/l |
At the end of treatment assessed up to 15 days
|
|
Blood glucose profile on glibenclamide
Zeitfenster: At the end of treatment assessed up to 15 days
|
Proportion of time spent within the target blood glucose range (≥ 4 and < 10 mmol/l) during the period of glibenclamide treatment |
At the end of treatment assessed up to 15 days
|
|
Blood glucose profile on glibenclamide
Zeitfenster: At the end of treatment assessed up to 15 days
|
Proportion of time spent above the target level (≥ 10 mmol/l) during the period of glibenclamide treatment |
At the end of treatment assessed up to 15 days
|
|
Blood glucose profile on glibenclamide
Zeitfenster: At the end of treatment assessed up to 15 days
|
Proportion of time spent in hypoglycemia (< 2.6 mmol/l) during the period of glibenclamide treatment |
At the end of treatment assessed up to 15 days
|
|
Duration of glibenclamide treatment
Zeitfenster: At the end of treatment assessed up to 15 days
|
Duration of glibenclamide treatment. |
At the end of treatment assessed up to 15 days
|
|
Nutritional intakes and growth
Zeitfenster: At the end of treatment assessed up to 15 days
|
Carbohydrate |
At the end of treatment assessed up to 15 days
|
|
Nutritional intakes and growth:
Zeitfenster: At the end of treatment assessed up to 15 days
|
lipid |
At the end of treatment assessed up to 15 days
|
|
Nutritional intakes and growth:
Zeitfenster: At the end of treatment assessed up to 15 days
|
protein |
At the end of treatment assessed up to 15 days
|
|
Nutritional intakes and growth:
Zeitfenster: At the end of treatment assessed up to 15 days
|
mean caloric intake (kcal/kg/day) during treatment |
At the end of treatment assessed up to 15 days
|
|
Nutritional intakes and growth:
Zeitfenster: At the end of treatment assessed up to 15 days
|
mean weight gain (g/kg/day) |
At the end of treatment assessed up to 15 days
|
|
Nutritional intakes and growth
Zeitfenster: At 36 week of amenorrhea corrected age
|
Carbohydrate |
At 36 week of amenorrhea corrected age
|
|
Nutritional intakes and growth:
Zeitfenster: At 36 week of amenorrhea corrected age
|
lipid |
At 36 week of amenorrhea corrected age
|
|
Nutritional intakes and growth:
Zeitfenster: At 36 week of amenorrhea corrected age
|
protein |
At 36 week of amenorrhea corrected age
|
|
Nutritional intakes and growth:
Zeitfenster: At 36 week of amenorrhea corrected age
|
mean caloric intake (kcal/kg/day) during treatment |
At 36 week of amenorrhea corrected age
|
|
Nutritional intakes and growth:
Zeitfenster: At 36 week of amenorrhea corrected age
|
mean weight gain ((g/kg/day) |
At 36 week of amenorrhea corrected age
|
|
Number of children with episode of hypoglycemia
Zeitfenster: At 72 hours after first administration
|
Number of children with at least one episode of moderate (blood glucose < 2.6 mmol/l) or severe (< 1.5 mmol/l) hypoglycemia |
At 72 hours after first administration
|
|
Number of children with episode of hypoglycemia
Zeitfenster: At the end of treatment assessed up to 15 days
|
Number of children with at least one episode of moderate (blood glucose < 2.6 mmol/l) or severe (< 1.5 mmol/l) hypoglycemia |
At the end of treatment assessed up to 15 days
|
|
Type of adverse reactions on glibenclamide
Zeitfenster: At 36 week of amenorrhea corrected age
|
evaluation of the type of adverse reactions identified during the study |
At 36 week of amenorrhea corrected age
|
|
Number of adverse reactions on glibenclamide
Zeitfenster: At 36 week of amenorrhea corrected age
|
evaluation of number of adverse reactions identified during the study |
At 36 week of amenorrhea corrected age
|
|
Number of participants with co-morbidity
Zeitfenster: At 36 week of amenorrhea corrected age
|
Neonatal morbidity assessed at 36 WA corrected age: intraventricular haemorrhage, periventricular leukomalacia, retinopathy of premature newborns, haemodynamic disorders, ulcerative necrotising enterocolitis |
At 36 week of amenorrhea corrected age
|
|
Mortality
Zeitfenster: At 36 week of amenorrhea corrected age
|
Mortality will be assessed |
At 36 week of amenorrhea corrected age
|
|
Dose adjustment
Zeitfenster: At the end of treatment assessed up to 15 days
|
Number of dose adjustments, to evaluate the easy of use |
At the end of treatment assessed up to 15 days
|
|
ease of use by caregivers
Zeitfenster: At day one of treatment
|
Assessment scores by visual-analogue scale for ease of use by caregivers; 0 as the lowest score, 10 as the highest score |
At day one of treatment
|
|
ease of use by caregivers
Zeitfenster: At day two of treatment
|
Assessment scores by visual-analogue scale for ease of use by caregivers; 0 as the lowest score, 10 as the highest score |
At day two of treatment
|
|
ease of use by caregivers
Zeitfenster: At day three of treatment
|
Assessment scores by visual-analogue scale for ease of use by caregivers; 0 as the lowest score, 10 as the highest score |
At day three of treatment
|
|
Plasma concentrations of glibenclamide
Zeitfenster: At 3 hours after the first administration
|
Evaluated by the pharmacokinetics study |
At 3 hours after the first administration
|
|
Plasma concentrations of glibenclamide
Zeitfenster: At 6 hours after the first administration
|
Evaluated by the pharmacokinetics study |
At 6 hours after the first administration
|
|
Plasma concentrations of glibenclamide
Zeitfenster: At 10 hours after the first administration
|
Evaluated by the pharmacokinetics study |
At 10 hours after the first administration
|
|
Plasma concentrations of glibenclamide
Zeitfenster: At 24 hours after the first administration
|
Evaluated by the pharmacokinetics study |
At 24 hours after the first administration
|
|
Plasma concentrations of glibenclamide
Zeitfenster: At 24 hours of blood glucose stabilization
|
Evaluated by the pharmacokinetics study |
At 24 hours of blood glucose stabilization
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Studienleiter: Jacques BELTRAND, Pr, Assistance Publique - Hôpitaux de Paris
- Studienleiter: Michel POLAK, Assistance Publique - Hôpitaux de Paris
- Studienleiter: Delphine MITANCHEZ, CHRU de Tours
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Stoffwechselerkrankungen
- Geburtshilfe, Frühgeburt
- Geburtsbedingte Geburtskomplikationen
- Schwangerschaftskomplikationen
- Störungen des Glukosestoffwechsels
- Ernährungs- und Stoffwechselerkrankungen
- Frühgeburt
- Hypoglykämie
- Schwefelverbindungen
- Organische Chemikalien
- Amides
- Sulfone
- Harnstoff
- Sulfonylharnstoffverbindungen
- Glyburid
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- P160916J
- 2021-005766-18 (EudraCT-Nummer)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .